Sitagliptin Combo Study

NCT01054118 Phase 1 COMPLETED

This study will assess the safety, tolerability, pharmacokinetics (explores what the body does to the drug), and pharmacodynamics (explores what a drug does to the body) of single doses of JNJ-38431055, sitagliptin, and co-administration of JNJ-38431055 and sitagliptin in healthy overweight or obese adult male volunteers.

Details

Lead sponsor	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase	Phase 1
Status	COMPLETED
Enrolment	18
Start date	2009-12
Completion	2010-02

Conditions

• Diabetes Mellitus, Type 2

Interventions

• JNJ-38431055
• Sitagliptin 100 mg
• JNJ-38431055 + Sitagliptin 100 mg
• Placebo

Primary outcomes

• GLP-1 levels after a standard meal — 0-4 hours after the standard meal

Countries

United States